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Sorafenib, a multikinase inhibitor, has been widely used to treat patients with advanced HCC in
clinic. We postulated that microRNAs (miRNA) might be involved in HCC target-chemotherapy with
sorafenib. MiRNA proﬁle of HepG2 was evaluated after cells were treated with vehicle or sorafenib
and alterations in miRNA expression occurred with 14 miRNAs. MiR-1274a, which is up-regulated by
sorafenib, could signiﬁcantly repress expression of ADAM9, a protease that is involved in sorafenib
target-therapy of HCC, in HCC cells. Taken together, our data emphasizes a new miRNA-based mech-
anism of sorafenib antitumor therapy.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the third common cause of
cancer mortality in the world [1]. The distribution of HCC is unbal-
anced throughout the world [2], with the highest incidence rates in
Asia and Sub-Saharan Africa [1]. Although primary prevention, par-
ticularly through mass vaccination of newborns against the hepa-
titis B virus, has been proved to be successful in many countries
[1–3], there are few effective treatment options for HCC patients
[4,5]. Especially, for patients diagnosed at an advanced stage or
with progression after locoregional therapy, no standard systemic
therapy was available before the advent of sorafenib [4–7].chemical Societies. Published by E
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activity in liver-cancer cell lines. It could also reduce tumor angio-
genesis and tumor-cell signaling and increase tumor-cell apoptosis
in a mouse xenograft model of human HCC [8]. It has been shown
that sorafenib can inhibit the activity of the serine/threonine
kinases c-Raf (Raf-1) and B-Raf; the mitogen-activated protein
kinases MEK and ERK; vascular endothelial growth factor receptors
(VEGFR)-1, 2, and 3; platelet derived growth factor receptors
(PDGFR)-a and b; the cytokine receptor c-KIT; the receptor
tyrosine kinases Flt-3 and RET; and the Janus kinase/signal
transducer and activator of transcription (JAK/STAT) pathway
[9–13]. Two Phase III studies showed clinical beneﬁts, including
prolonged overall survival and/or time to progression, in both
Caucasian and Asia-Paciﬁc patients with advanced HCC treated
with sorafenib [4,5]. As a result, sorafenib has been proved for clin-
ical application for advanced HCC patients in many countries.
Recently, Kohga et al. reported that increased a disintegrin and
metalloproteinase 9 (ADAM9) expression in human HCC compared
with normal liver tissues [14]. ADAM9 can cleave cell membrane-
bound major histocompatibility complex class I-related chain A
(MICA) in HCC cells, which may decrease NK cell sensitivity to
HCC cells and result in escape of HCC to antitumor immunity.lsevier B.V. All rights reserved.
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ADAM9, increased expression of membrane-bound MICA, and de-
creased levels of soluble MICA in HCC cells. Therefore, sorafenib
could enhance NK sensitivity of HCC cells via increased expression
of membrane-bound MICA [14]. These results demonstrate that
sorafenib therapy may have a previously unrecognized effect on
antitumor immunity in patients with HCC. However, it is still
unclear how ADAM9 expression was inhibited by sorafenib.
MicroRNAs (miRNAs) are small RNAs that bind to target mRNA
acting as posttranscriptional gene expression regulators [15]. By
pairing to complementary binding sites within the 30 untranslated
region (30 UTR) of hundreds of target mRNAs, miRNAs impair their
translation or promote their degradation, thus participating in the
control of crucial processes. Previous studies demonstrated impor-
tant roles of miRNAs in HCC development and progression [16–18].
In addition, it has also been shown that miR-193b, miR-122 and
Let-7c could modify the response of HCC cells to sorafenib treat-
ment [19–21]. However, it is still largely unknown how sorafenib
inﬂuences global miRNA expression proﬁle changes and effects of
sorafenib-induced miRNAs on HCC cells.
In the current study, we compared miRNA expression proﬁles of
HepG2 cells treated with or without sorafenib and found that
miR-1274a is signiﬁcantly up-regulated after drug treatment.
Additionally, ADAM9, which is suppressed in HCC cells by sorafe-
nib, can be greatly down-regulated by miR-1274a. These results
provide a new mechanism how miRNAs are involved in sorafenib
target-therapy of HCC.2. Materials and methods
2.1. Cell culture and cell proliferation assay
HepG2 (American Type Culture Collection, ATCC: HB-8065) and
PLC/PRF/5 (ATCC: CRL-8024) human HCC tumor cells were cul-
tured with RPMI 1640 supplemented with 10% fetal bovine serum
(FBS) in a humidiﬁed incubator containing 5% CO2 at 37 C.
Sorafenib [N-(3-triﬂuoromethyl-4-chlorophenyl)-N-(4-(2-meth-
ylcarbamoyl pyridin-4-yl) oxyphenyl) urea] (LC Laboratories, Wo-
burn, MA, US) was dissolved in 100% dimethyl sulfoxide (DMSO)
(Sigma) to the ﬁnal concentrations of 0.05, 0.25, 1 and 5 lmol/L.
For all cell proliferation studies, cells were inoculated in 96-well
plates. After being cultured for 24 h, cells were treated with DMSO
or 0.05, 0.25, 1 and 5 lmol/L sorafenib. Tetrazolium salt (WST-1;
Roche Applied Science) cell proliferation assay was then carried
out at various days after drug treatment, following the manufac-
ture instruction.
2.2. TUNEL assay
After HepG2 cells were treated with 5 lmol/L sorafenib for 24 h,
cellular DNA fragmentation was measured with the ApoTag Red
in situ Apoptosis detection kit (Chemicon International, CA, USA)
according to the manufacturer’s instructions. To quantify the apop-
totic cells, the terminal deoxynucleotidyl transferase-mediated
nick end labeling (TUNEL)-positive cells were counted using a con-
focal microscopy.
2.3. RNA extraction, reverse transcription, and real-time PCR miRNA
quantiﬁcation
Total RNA was extracted from HepG2 cells treated with DMSO,
0.05 lmol/L sorafenib or 1 lmol/L sorafenib for 24 h using Trizol
reagent (Invitrogen). After reverse transcription with a TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems), PCR
array assays were conducted using TaqMan MicroRNA ArrayHuman MicroRNA A+B Cards Set v3.0 (Applied Biosystems). In
brief, all 754 human mature miRNAs and 3 endogenous controls
were reverse transcribed using Megaplex™ PreAmp primers. The
reverse transcription products were subsequently loaded onto
the TaqMan Array to do real-time PCR ampliﬁcation using Applied
Biosystems 7900HT Fast Real-Time PCR System. miRNA expression
was measured using Ct value (threshold cycle). The DDCt method
for relative quantitation of gene expression was used to determine
miRNA expression levels. The DCt was calculated by subtracting
the Ct of U6 RNA from the Ct of the miRNA of interest. The DDCt
was calculated by subtracting the DCt of the reference sample
(HepG2 cells treated with DMSO) from the DCt of each sample
(HepG2 cells treated with 0.05 lmol/L or 1 lmol/L sorafenib). Fold
change was generated using the equation 2DDCt.
To validate the expression level measurements of miR-30a-3p,
miR-194⁄, miR-219-1-3p, miR-522, miR-548c-5p, miR-629,
miR-664, miR-1260, miR-1274a, miR-1274b, miR-1290, miR-
1291, miR-222⁄, miR-548b-5p and U6, cDNA synthesis and subse-
quent real-time PCR were done using a TaqMan MiRNA Reverse
Transcription kit (Applied Biosystems), individual TaqMan MiRNA
assay (Applied Biosystems), and Applied Biosystems 7500HT Fast
Real-Time PCR System following the manufacture instructions.
2.4. miRNA target prediction and luciferase activity assay
The analysis of miR-1274a predicted targets was determined
using the algorithm TargetScan Human 5.1 (http://www.target-
scan.org/).
A 449-bp fragment of the human ADAM9 30-UTR (spanning
from nucleotides 2538 to 2986) was ampliﬁed by PCR using prim-
ers ADAM9-3F (50-ATTTTTTTAACCTTCTTTTTGC-30) and ADAM9-3R
(50-GGCAGCTGATTAGTCAGTTTTC-30) and was cloned downstream
of the ﬁreﬂy luciferase gene present in the pMIR-REPORT vector
(Ambion) to develop the pMIR-ADAM9 30-UTR-WT plasmid. HepG2
and PLC/PRF/5 cells were cultured in 24-well plates and each trans-
fected with 50 ng of either pMIR-ADAM9 30-UTR-WT or pMIR-
REPORT together with 1 ng pRL-SV40 vector (Promega), which con-
tains the Renilla luciferase gene, and 30 pmol miR-1274a mimics
or negative control #2 (Ambion). Transfection was done using
Lipofectamine™ 2000 (Invitrogen). At 24 h after transfection, ﬁre-
ﬂy and Renilla luciferase activities were examined using the
Dual-Luciferase Reporter Assay (Promega). Each transfection was
repeated in triplicate.
Furthermore, pMIR-ADAM9 30-UTR-WT was mutated in the ﬁrst
four nucleotides of the seed-match sequence for miR-1274a (Origi-
nal seed-match sequence: CAGGGA; Mutated seed-match
sequence: TGAAGA). When the ﬁrst seed-match sequence of
pMIR-ADAM9 30-UTR-WT was mutated, the plasmid was named
as pMIR-ADAM9 30-UTR-M1. The plasmid with the mutated second
seed-match sequence of pMIR-ADAM9 30-UTR-WT was called
pMIR-ADAM9 30-UTR-M2. The plasmid with both mutated seed-
match sequences of pMIR-ADAM9 30-UTR-WT was named as
pMIR-ADAM9 30-UTR-M3. pMIR-ADAM9 30-UTR-M1, pMIR-ADAM9
30-UTR-M2 or pMIR-ADAM9 30-UTR-M3 was cotransfected with
miR-1274a mimics or negative control #2 to HepG2 and PLC/
PRF/5 cells as described above. At 24 h after transfection, luciferase
activities were examined. Each transfection was also repeated in
triplicate.
2.5. Real-time RT-PCR and Western blot analysis of ADAM9 expression
HepG2 and PLC/PRF/5 cells either treated with 1 lmol/L sorafe-
nib and DMSO or transfected with miR-1274a mimics and negative
control RNA (Ambion) were collected 24 h after drug treatment or
transfection. ADAM9 and GAPDH real-time PCR primer and probe
sets (Assay ID: Hs00177638_m1 and Hs02758991_g1, respec-
Fig. 1. Effects of sorafenib on proliferation and apoptosis of HepG2 cells. (A) Effects
of different concentrations of sorafenib on the growth of HepG2. WST-1 analysis of
the growth of HepG2 cells that were treated with DMSO and 0.05, 0.25, 1 or 5 lmol/
1830 C. Zhou et al. / FEBS Letters 585 (2011) 1828–1834tively) were inventoried products of Applied Biosystem. GAPDH
mRNA from each sample was quantiﬁed as an endogenous control
of internal RNA. Analyses were performed using a standard
TaqMan PCR Kit protocol. Experiments were carried out in tripli-
cate for each data point.
For Western blot analysis, HepG2 and PLC/PRF/5 cells either
treated with 1 lmol/L sorafenib and DMSO or transfected with
miR-1274a mimics and negative control RNA were lysed for
15 min at 4 C with the RIPA buffer and centrifuged at 10,000g
for 15 min. The supernatants were collected, and 30 lg of extract
was separated in 10% SDS–PAGE and then blotted onto nitrocellu-
lose membrane (Immobilon-NC, Millipore). ADAM9 was detected
with the monoclonal anti-ADAM9 antibody (R&D Systems) at
4 C overnight. An anti-mouse horseradish peroxidase (HRP)-con-
jugated secondary antibody (Santa Cruz) was used for visualization
of ADAM9. For b-actin detection, we used a rabbit polyclonal anti-
body together with an anti-rabbit HRP-conjugated secondary anti-
body (Santa Cruz). SuperSignal chemiluminescence kit (Pierce) for
the detection of blots was used according to the manufacturer’s
instructions.
2.6. Statistical analysis
Differences between groups were analyzed using a double-sided
Student’s t test, when two groups were present. Experimental data
are expressed asmean ± standard deviation of three separate exper-
iments done in triplicate. P values <0.05 were considered statisti-
cally signiﬁcant. Statistical analysis were done using SPSS version
11.5.L sorafenib. (B) TUNEL assay. HepG2 cells were treated with 5 lmol/L sorafenib or
DMSO. Percentage of TUNEL-positive cells was quantiﬁed using a confocal
microscopy. Triplicate experiments were performed for each set. Points, mean
(n = 3); bars, standard deviation.3. Results
3.1. Sorafenib signiﬁcantly inhibits HepG2 cell proliferation and
induces apoptosis
To investigate the involvement of miRNAs in pharmacological
effects of sorafenib on HCC cells, we ﬁrstly examined the inhibition
effects of different concentrations of sorafenib on HepG2 cells. Cell
proliferation was measured by WST-1 assay for 5 days after adding
sorafenib into HepG2 cells. It was found that different concentra-
tions of sorafenib could inhibit HepG2 cell proliferation differen-
tially (Fig. 1A). When cells treated with 0.05, 0.25, 1 or 5 lmol/L
sorafenib for 24 h, about 27%, 53%, 50% or 91% decreased cell
growth was observed compared with controls (all P < 0.05). After
0.05, 0.25, 1 and 5 lmol/L sorafenib treatment for 5 days, cell pro-
liferation was reduced to 60%, 42%, 11% and 2% compared with
controls (all P < 0.01). It was shown that no obvious cell growth
could be found when cells treated with more than 1 lmol/L
sorafenib from day 1 to day 5 (Fig. 1A), demonstrating that
1 lmol/L sorafenib is sufﬁcient to consistently inhibit HepG2 cell
proliferation. When cells treated with less than 1 lmol/L sorafenib,
apparent increased cell growth could still be found from day 1 to
day 5 and the cell proliferation rate increased with the decrease
of sorafenib used (Fig. 1A). Therefore, we used both 0.05 and
1 lmol/L of sorafenib to evaluate its biological effect on inducing
changes of miRNA proﬁle of HepG2 cells with low or high cytotox-
icity. Sorafenib treatment-induced apoptosis was assessed by
TUNEL staining. As shown in Fig. 1B, sorafenib led to apoptosis in
20 ± 3.2 percent of drug-treated HepG2 cells compared to 1 ± 0.4
percent in DMSO-treated cells after 24 h (P < 0.01).
3.2. miR-1274a is up-regulated in HCC cells treated with sorafenib
MiRNA expression proﬁling of HepG2 cells treated with DMSO,
0.05 lmol/L sorafenib or 1 lmol/L sorafenib for 24 h was per-formed in triplex. Pairwise signiﬁcance analysis of the proﬁling
data indicated that the expression of 12 miRNAs (miR-30a-3p,
miR-194⁄, miR-219-1-3p, miR-522, miR-548c-5p, miR-629,
miR-664, miR-1260, miR-1274a, miR-1274b, miR-1290, and miR-
1291) was signiﬁcantly up-regulated in HepG2 cells treated with
both 0.05 lmol/L and 1 lmol/L sorafenib (>2-fold) compared with
those in HepG2 cells treated with DMSO (Table 1). Additionally, the
expression of miR-222⁄ and miR-548b-5p was reproducibly down-
regulated in HepG2 cells treated with both 0.05 lmol/L and
1 lmol/L sorafenib (>2-fold) compared with those in HepG2 cells
treated with DMSO (Table 1). In all these fourteen miRNAs,
miR-1274a showed highest basal expression levels (Ct value of
miR-1274a vs. Ct value of U6 RNA: 17.02 ± 0.12 vs. 14.25 ± 0.15)
and moderate expression changes in HepG2 cells with or without
sorafenib treatment (2.58- and 4.73-fold changes after adding
0.05 lmol/L and 1 lmol/L sorafenib).
To validate the differential expression patterns of these 14
miRNAs revealed by proﬁle analysis, we performed qRT-PCR for
each individual miRNA in two HCC cell lines, HepG2 and PLC/
PRF/5 treated with DMSO or 1 lmol/L sorafenib (Fig. 2). The anal-
ysis conﬁrmed that expression of miR-30a-3p, miR-194⁄, miR-219-
1-3p, miR-522, miR-548c-5p, miR-629, miR-664, miR-1260,
miR-1274a, miR-1274b, miR-1290, and miR-1291 was up-regu-
lated and expression of miR-222⁄ and miR-548b-5p is down-regu-
lated in HCC cells treated with sorafenib compared with those in
HCC cells treated with vehicle. Similarly to the above miRNA pro-
ﬁling data, miR-1274a showedmost abundant intracellular expres-
sion among all the 14 differentially expressed miRNAs and
moderate expression changes in both HepG2 and PLC/PRF/5 cell
lines. Based on these observations, we decided to focus on the sig-
niﬁcance of miR-1274a in the pharmacological effects of sorafenib
on HCC cells.
Table 1
miRNAs differentially expressed in HepG2 cells before and after sorafenib treatment.
miRNA Chromosome location Fold change* P-value Fold change P-value
Up-regulated miRNAs
miR-30a-3p 6q13 2.24 0.042 2.56 0.021
miR-194⁄ 11q13.1 2.14 0.038 2.21 0.033
miR-219-1-3p 6p21.32 2.50 0.027 2.58 0.023
miR-522 19q13.42 2.41 0.012 3.06 0.011
miR-548c-5p 12q14.2 2.45 0.044 3.55 0.041
miR-629 15q23 2.64 0.002 7.70 <0.001
miR-664 1q41 5.64 <0.001 9.87 <0.001
miR-1260 14q24.3 2.12 0.044 2.04 0.038
miR-1274a 5p13.1 2.58 0.009 4.73 0.003
miR-1274b 19q13.43 2.62 0.031 4.84 0.025
miR-1290 1p36.13 2.27 0.042 2.56 0.037
miR-1291 12q13.12 6.73 0.006 12.46 0.005
Down-regulated miRNAs
miR-222⁄ Xp11.3 0.43 0.012 0.33 0.008
miR-548b-5p 6q22.31 0.41 0.005 0.29 0.002
Note: All experiments were done in triplex.
* Cells treated with 0.05 lmol/L sorafenib or DMSO for 24 h. Only those miRNAs whose expression levels displayed >0.5-fold decrease or twofold
increase in HepG2 cells after sorafenib treatment were listed.
 Cells treated with 1 lmol/L sorafenib or DMSO for 24 h. Only those miRNAs whose expression levels displayed >0.5-fold decrease or twofold
increase in HepG2 cells after sorafenib treatment were listed.
 P value <0.05 was considered statistically signiﬁcant.
Fig. 2. The relative expression of selected miRNAs in HepG2 and PLC/PRF/5 cell lines treated with DMSO or 1 lmol/L sorafenib. Twenty-ﬁve nanograms of total RNA from each
cell line were used to measure miRNA expression levels by qRT-PCR. All of the data were normalized by the U6 expression level and presented as the relative expression level.
The relative expression level of each miRNA in HepG2 and PLC/PRF/5 cells treated with DMSO was arbitrarily set as 1.0.
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targeting its 30UTR
To begin unraveling the potential role of miR-1274a in thera-
peutic responses to sorafenib in HCC, putative human protein-
coding gene targets of miR-1274a were identiﬁed by using the Tar-
getScan algorithm. The analysis revealed that the ADAM9 gene
30UTR harbors two putative binding sites for miR-1274a (position
31–37 and position 194–200 of ADAM9 30UTR) (Fig. 3A). To exam-
ine the potential interaction between miR-1274a and ADAM9
30UTR, the human ADAM9 30UTR was subcloned in pMIR-REPORT
and co-transfected into HepG2 and PLC/PRF/5 cells with
miR-1274a mimics. miR-1274a transfected HepG2 or PLC/PRF/5
cells showed a 40% or 32% decrease of relative luciferase activity
compared with the negative control small RNA-transfected cells
(both P < 0.001) (Fig. 3B). When HCC cells were transfected with
both miR-1274a mimics and plasmids harboring one mutated
miR-1274a seed-match sequence (pMIR-ADAM9 30-UTR-M1 or
pMIR-ADAM9 30-UTR-M2), a 25% or 29% (HepG2) and 16% or 12%
(PLC/PRF/5) decreased relative luciferase activity was also ob-
served compared with the negative control group (all P < 0.05)Fig. 3. Pairing site between miR-1274a and ADAM9 30-UTR and the dual-luciferase repo
human ADAM9 gene. Two pairing sites can be found in the 30 UTR of the human ADAM9
after the luciferase coding sequence (pMIR-ADAM9 30-UTR-WT). pMIR-ADAM9 30-UTR
mimics or negative control RNA #2. Luciferase activity was normalized relative to a simu
sequence of pMIR-ADAM9 30-UTR-WT was mutated, the plasmid was named as pMIR-A
pMIR-ADAM9 30-UTR-WT was called pMIR-ADAM9 30-UTR-M2. The plasmid with both
ADAM9 30-UTR-M3. Inhibition effects of miR-1274a mimics on pMIR-ADAM9 30-UTR-M1
and E. Results of the mean of triplicate assays with standard deviation of the mean are(Fig. 3C and D). In contrast, the luciferase activity of double mutant
reporter (pMIR-ADAM9 30-UTR-M3) was unaffected by simulta-
neous transfection of miR-1274a in HepG2 or PLC/PRF/5 cells (both
P > 0.05) (Fig. 3E), indicating that miR-1274a may suppress gene
expression through both miR-1274a-binding sequences at the
30UTR of ADAM9.
To further determine whether ADAM9 was a target gene of miR-
1274a, we detected ADAM9 mRNA and protein expression levels in
HepG2 and PLC/PRF/5 cells with or without miR-1274a mimic
expression. As shown in Fig. 4A, sorafenib can signiﬁcantly sup-
press ADAM9 mRNA expression in both HepG2 and PLC/PRF/5 cells
(both P < 0.05). Overexpression of miR-1274a in HCC cells could
also signiﬁcantly reduce ADAM9mRNA expression by 33% (HepG2)
and 30% (PLC/PRF/5) compared with cells transfected with negative
control small RNA (both P < 0.05). Western blot analysis showed
that forced expression of miR-1274a in HCC cells resulted in a sig-
niﬁcant reduction of ADAM9 expression (Fig. 4B). Similarly, when
HepG2 and PLC/PRF/5 cells were treated with sorafenib, decreased
ADAM9 protein expression could also be observed (Fig. 4B). These
results strongly indicate that ADAM9 gene expression is directly
suppressed by miR-1274a.rter gene assay. (A) TargetScan predicted pairing of miR-1274a to the 30-UTR of the
gene. (B) The 30 UTR of ADAM9 was inserted in the pMIR-REPORT reporter plasmid
-WT was cotransfected into HepG2 and PLC/PRF/5 cells with 30 pmol miR-1274a
ltaneously transfected Renilla expression plasmid. (C–E) When the ﬁrst seed-match
DAM9 30-UTR-M1. The plasmid with the mutated second seed-match sequence of
mutated seed-match sequences of pMIR-ADAM9 30-UTR-WT was named as pMIR-
, pMIR-ADAM9 30-UTR-M2 and pMIR-ADAM9 30-UTR-M3 were shown in panel C, D,
presented. ⁄P < 0.05, ⁄⁄P < 0.001.
Fig. 4. Inverse correlation between miR-1274a and ADAM9 mRNA and protein
levels in HepG2 and PLC/PRF/5 cell lines. (A) Real-time RT-PCR analysis of ADAM9
expression in HepG2 and PLC/PRF/5 cell lines either treated with 1 lmol/L sorafenib
and DMSO or transfected with miR-1274a mimics and negative control RNA.
GAPDH mRNA from each sample was quantiﬁed as an endogenous control of
internal RNA. Each determination was done in triplicate. Mean ± standard devia-
tion. ⁄P < 0.05. (B) Western blot assay of ADAM9 protein expression in HepG2 and
PLC/PRF/5 cell lines normalized based on b-actin expression. HepG2 and PLC/PRF/5
cell lines were also either treated with 1 lmol/L sorafenib and DMSO or transfected

















Fig. 5. A schematic diagram illustrating how miR-1274a is involved in sorafenib
target-chemothearapy.
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Accumulated evidences have shown that miRNAs can regulate
many fundamental cellular processes and cancer development
[22]. A number of miRNAs, which function as oncogenes or tumor
suppressors, are called ‘‘oncomirs’’ now [23]. Despite it is known
that certain miRNAs impart drug resistance [24] or sensitivity
[25] to cancer cells, relatively little is known about the molecular
details on how speciﬁc miRNAs regulate biological pathways in-
volved in target-chemotherapy.
Sorafenib is the current standard chemotherapy in patients with
advanced HCC. Multiple kinase pathways have been found to be
inhibited by sorafenib, including Raf kinase dependent or indepen-
dent pathways, VEGFR and PDGFR pathway and Mcl-1 [8–13].
Through suppression of these abovementionedpathways, sorafenib
can inhibit cell proliferation, angiogenesis and apoptosis of HCC
in vitro and in vivo [8–13]. Although altered expression of miRNAs
in primary human HCC has been found to be correlated to tumor
development and progression [16–18], the potential involvement
of miRNAs in therapeutic effects of sorafenib on HCC has not been
explored. We observed signiﬁcantly increased expression of 12
miRNAs and down-regulation of twomiRNAs in HepG2 cells treated
with sorafenib compared with cells treated with vehicle. Based on
published literatures, none of these 14 differentially sorafenib-reg-
ulatedmiRNAswas related to HCC etiology and prognosis. These re-
sults demonstrate that there might be different mechanisms how
miRNAs are involved in pharmacological effects of sorafenib on
HCC.
It was found that sorafenib therapy may also play a part in
antitumor immunity in HCC patients [14]. One of the important
mechanisms by which tumor cells escape from NK cell mediated
immunosurveillance is MICA shedding [26], which is associated
with the cleave of the extracellular domain of MICA to produce
soluble MICA. ADAM9 plays an essential role in cleavage of
membrane MICA. Interestingly, over-expression of ADAM9 wasobserved in human HCC tissues compared with normal liver tis-
sues [27], indicating suppressed antitumor immunity through in-
creased MICA shedding mediated by ADAM9. Kohga et al.
reported that sorafenib could remodel HCC cells by down-regu-
lating ADAM9 expressions, thereby inhibiting MICA ectodomain
shedding and enhancing sensitivity to NK cells [14]. However,
it is still largely unknown how sorafenib inhibit ADAM9
expression.
ADAM9, also known as MDC9 (metalloproteinase/disintegrin/
cysteine-rich protein 9), MCMP (myeloma cell metalloproteinase),
and meltrin-c, comprises a subgroup of ADAMs that also contains
ADAM12 and ADAM15 [28]. Besides MICA, ADAM9 also cleaves
heparin-binding epidermal growth factor (EGF; Ref. [29]), Delta-
like 1, a Notch ligand [30], as well as ADAM10 [31,32]. Although
there are no reports on how ADAM9 is regulated by miRNAs, we
found that miR-1274a could be signiﬁcantly up-regulated after
adding sorafenib in HCC cells and greatly reduce ADAM9 expres-
sion in HCC cells by directly binding to ADAM9 30UTR. These re-
sults suggest that miR-1274a may act as an important regulator
in sorafenib target-chemothearapy and emphasizes a new miR-
NA-based mechanism of sorafenib antitumor therapy (Fig. 5).
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